Business Context and Reporting Period
Company: ARDELYX, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2024
Event: Entry into a Material Definitive Agreement (Commercial Supply Agreement).
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document solely reports the execution of a commercial contract.
Material Changes and Agreement Details
On August 7, 2024, Ardelyx, Inc. entered into a Commercial Supply Agreement with Catalent Pharma Solutions, LLC, effective as of July 23, 2024.
- Scope: Catalent will perform tableting, testing, release, and bulk packaging of the product IBSRELA®.
- Volume Commitment: Ardelyx agreed to purchase a minimum number of batches per contract year.
- Pricing: Unit prices are fixed with annual adjustments starting January 1, 2025, based on the increase in the applicable producer price index. Additional maintenance fees and expenses apply.
- Term: The initial term runs until December 31, 2028, with automatic renewals for successive two-year terms thereafter.
- Termination: Either party may terminate for material breach or other extenuating circumstances following applicable cure periods.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard contractual termination clauses. The agreement is intended to secure manufacturing capacity for IBSRELA®.
Investor Verification Checklist
- Review the full text of the Commercial Supply Agreement (Exhibit 10.1) for specific batch minimums and pricing details, as portions were redacted in the filing summary.
- Verify the impact of the annual producer price index adjustment on future cost of goods sold.
- Confirm the current production capacity requirements for IBSRELA® relative to the minimum batch commitments.
- Monitor subsequent filings for any amendments to the agreement or changes in manufacturing strategy.